Revolution Medicines, Inc. (RVMDW) stock
RVMDWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMD
$9.81+0.18 (+1.82%)
Close on Oct 30, 2026Market cap $41.00BP/E –Yield –
Revolution Medicines r&d expenses
Research and development expenses are spending on new products and technology.
Revolution Medicines's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.30B, up 68.4% year over year. For fiscal 2025 it was $987.33M, up 66.7% from the year before. The highest annual figure on record is $987.33M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $987.33M | +66.7% |
| FY2024 | Dec 31, 2024 | $592.23M | +40.0% |
| FY2023 | Dec 31, 2023 | $423.14M | +67.2% |
| FY2022 | Dec 31, 2022 | $253.07M | +35.4% |
| FY2021 | Dec 31, 2021 | $186.95M | +41.4% |
| FY2020 | Dec 31, 2020 | $132.25M | +44.1% |
| FY2019 | Dec 31, 2019 | $91.76M | +79.6% |
| FY2018 | Dec 31, 2018 | $51.08M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $394.92M | +76.2% |
| Q1 FY2026 | Mar 31, 2026 | $343.97M | +67.2% |
| Q4 FY2025 | Dec 31, 2025 | $294.94M | +56.8% |
| Q3 FY2025 | Sep 30, 2025 | $262.51M | +73.0% |
| Q2 FY2025 | Jun 30, 2025 | $224.13M | +66.1% |
| Q1 FY2025 | Mar 31, 2025 | $205.75M | +74.3% |
| Q4 FY2024 | Dec 31, 2024 | $188.10M | +26.7% |
| Q3 FY2024 | Sep 30, 2024 | $151.75M | +40.9% |
| Q2 FY2024 | Jun 30, 2024 | $134.93M | +37.7% |
| Q1 FY2024 | Mar 31, 2024 | $118.02M | +71.2% |
| Q4 FY2023 | Dec 31, 2023 | $148.48M | +124.5% |
| Q3 FY2023 | Sep 30, 2023 | $107.74M | +55.1% |
| Q2 FY2023 | Jun 30, 2023 | $97.98M | +60.6% |
| Q1 FY2023 | Mar 31, 2023 | $68.95M | +22.1% |
| Q4 FY2022 | Dec 31, 2022 | $66.13M | +23.2% |
| Q3 FY2022 | Sep 30, 2022 | $69.46M | +49.5% |
| Q2 FY2022 | Jun 30, 2022 | $61.00M | +32.8% |
| Q1 FY2022 | Mar 31, 2022 | $56.49M | +38.3% |
| Q4 FY2021 | Dec 31, 2021 | $53.68M | +45.1% |
| Q3 FY2021 | Sep 30, 2021 | $46.47M | +33.3% |
| Q2 FY2021 | Jun 30, 2021 | $45.94M | +39.5% |
| Q1 FY2021 | Mar 31, 2021 | $40.86M | +48.8% |
| Q4 FY2020 | Dec 31, 2020 | $37.01M | +34.6% |
| Q3 FY2020 | Sep 30, 2020 | $34.87M | +51.9% |
| Q2 FY2020 | Jun 30, 2020 | $32.92M | +63.6% |
| Q1 FY2020 | Mar 31, 2020 | $27.46M | +29.6% |
| Q4 FY2019 | Dec 31, 2019 | $27.49M | – |
| Q3 FY2019 | Sep 30, 2019 | $22.96M | – |
| Q2 FY2019 | Jun 30, 2019 | $20.12M | – |
| Q1 FY2019 | Mar 31, 2019 | $21.19M | – |